{"nctId":"NCT02358343","briefTitle":"A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}","startDateStruct":{"date":"2015-03-23","type":"ACTUAL"},"conditions":["Depression","End Stage Renal Disease"],"count":184,"armGroups":[{"label":"Engagement Interview","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Engagement Interview"]},{"label":"Control Visit","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Cognitive Behavioral Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Cognitive Behavioral Therapy"]},{"label":"Antidepressant Drug Therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Antidepressant Drug Therapy"]},{"label":"Observational Cohort","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Engagement Interview","otherNames":[]},{"name":"Cognitive Behavioral Therapy","otherNames":["CBT"]},{"name":"Antidepressant Drug Therapy","otherNames":["Sertraline, \"Zoloft\""]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥ 21 years;\n2. Undergoing thrice-weekly maintenance HD for ≥ 3 months;\n3. Able to speak either English or Spanish;\n4. BDI-II score ≥ 15; and\n5. Meets diagnostic criteria for either current major depressive episode or dysthymia on the MINI.\n\nExclusion Criteria:\n\n1. Active suicidal intent;\n2. Ongoing psychotherapy or current treatment with certain anti-depressant drugs;\n3. Evidence of cognitive impairment on Mini-Cog;\n4. Present or past psychosis or bipolar disorder I or II on the MINI;\n5. Alcohol or substance abuse diagnosed on the MINI or history of such abuse in the past three months;\n6. Life expectancy \\< 3 months, in the judgment of the site principal investigator;\n7. Anticipated to receive living related donor kidney transplantation within 3 months;\n8. Pregnancy, or lactation, or women of childbearing age not willing to use adequate birth control;\n9. Clinical and/or laboratory evidence of chronic liver disease;\n10. History of significant active bleeding in the past three months, such as hospitalization for gastrointestinal bleeding;\n11. Current use of class I anti-arrhythmic medications (e.g., propafenone, flecainide), pimozide, monoamine oxidase inhibitors, reserpine, guanethidine, cimetidine, tri-cyclic anti-depressants, triptans, tramadol, linezolid, tryptophan, and St. John's wort; and\n12. Known hypersensitivity to sertraline.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Initiated Depression Treatment","description":"The primary measure of efficacy of the Engagement Interview will be the number of patients undergoing hemodialysis with co-morbid depression who initiate treatment for the condition.\n\nThis will be defined as one of the following:\n\n* Completing at least one psychotherapy session either as a part of the clinical trial or in the community within four weeks of establishing a diagnosis of major depression and/or dysthymia.\n* Receiving a supply of anti-depressant drug either as a part of the clinical trial or the treating physician within four weeks of establishing a diagnosis of major depression and/or dysthymia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"PRIMARY","title":"QIDS-C Score","description":"The Quick Inventory of Depressive Symptomatology Clinician-rated (QIDS-C) scale ranges from 0-27, higher scores indicate worse depression. The primary measure of efficacy of Intervention will be the mean difference in QIDS-C score at Week 12 between treatment groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Accepted Depression Treatment","description":"The secondary measure of efficacy of the Engagement Interview will be the % of patients undergoing hemodialysis with co-morbid depression who are willing to accept treatment.\n\nThis will be measured by the patient's intent and will be defined as one of the following:\n\n* Signing the informed consent to be randomly assigned to individual CBT or drug therapy\n* Receiving a referral by the research team and/or primary care physician and/or treating nephrologist to a therapist for psychotherapy in the community.\n* Receiving a prescription for anti-depressant drug therapy from primary care physician and/or treating nephrologist within two weeks of establishing a diagnosis of major depression/dysthymia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"BDI-II","description":"Beck Depression Inventory-II, range 0-63, higher scores indicate worse depression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]}]},{"type":"SECONDARY","title":"GAD-7","description":"Generalized Anxiety Disorder 7-item Scale, range 0-21, higher scores indicate worse anxiety","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sheehan Disability Scale","description":"range 0-30, higher scores indicate worse disability","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]}]},{"type":"SECONDARY","title":"SF-36 Energy/Vitality","description":"Energy/vitality subscale of the 36-Item Short Form Health Survey, range 0-100, higher scores indicate better energy/vitality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Quality of Life Scale","description":"range 0-10, higher scores indicate better quality of life","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Satisfaction With Life Scale","description":"range 1-35, higher scores indicate better satisfaction","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"20.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Perceived Social Support","description":"Multi-Dimensional Scale of Perceived Social Support, range 1-7, higher scores indicate better social support","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"SECONDARY","title":"PSQI","description":"Pittsburgh Sleep Quality Index, range 0-21, higher scores indicate worse sleep quality","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Exercise","description":"Single item activity measure, range 1-6, higher indicates less activity","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Dialysis Treatment Sessions Skipped and/or Shortened","description":"Treatment Adherence with Dialysis as defined by the percentage of all dialysis sessions skipped and/or requested by the patient to be shortened by ≥ 10 minutes over the 12-week intervention period. Dialysis sessions missed due to hospitalization will not be included as a skipped treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Inter-dialytic Weight Gain","description":"Treatment Adherence with Fluid Intake as defined by inter-dialytic weight gain (as % of post-dialysis weight) during Week 12 of the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Phosphorus Level","description":"Treatment Adherence with Diet and/or Medications as defined by Serum phosphorus level measured as a part of routine clinical care during the third month of participation in the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":60},"commonTop":["Vomiting","Dizziness","Fatigue"]}}}